Medigene 和 WuXi 生物生物学合作伙伴,为期3年,以开发治疗难以治疗肿瘤的TCR-TCEs。 Medigene and WuXi Biologics partner for 3 years to develop TCR-TCEs for treating difficult-to-treat tumors.

Medigene和WuXi生物logics伙伴,为期3年,开发TCR制导T细胞注射器(TCR-TCEs),用于治疗难以治疗的肿瘤。 Medigene and WuXi Biologics partner for 3 years to develop TCR-guided T cell engagers (TCR-TCEs) for treating difficult-to-treat tumors. Medigene的TCR专门知识与WuXi生物实验的TCE平台、WuXiBodyTM和反CD3 mAb相结合, 合作的目的是改善癌症治疗, 加速新疗法的发现和发展。 Combining Medigene's TCR expertise with WuXi Biologics' TCE platform, WuXiBody™, and anti-CD3 mAb, the collaboration aims to improve cancer treatments and accelerate novel therapy discovery and development. 预计到2030年,两用疗法的市场将达到80bn。 The market for bispecific therapies is projected to reach $80bn by 2030.